Abivax SA (ABVX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABVX SEC filings page.
Abivax SA (ABVX) reported $5.4M in revenue for fiscal year 2025, down 58.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Abivax SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Abivax SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Abivax SA had 79M shares outstanding at the end of fiscal year 2025, against 63M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Abivax SA scores 47/100 among other emerging companies.
Abivax SA spent $208.6M on research and development in fiscal year 2025, which was 70.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Abivax SA scores 91/100 among other emerging companies.
Abivax SA reported revenue of $5.4M in fiscal year 2025, against $12.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Abivax SA scores 47/100 among other emerging companies.
Abivax SA's operations used $189.1M of cash in fiscal year 2025, against $159.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Abivax SA scores 23/100 among other emerging companies.
Not available for Abivax SA, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Abivax SA passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Abivax SA reported a net loss of $394.4M while operations used $189.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Abivax SA reported an operating loss of $288.8M against $111K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Abivax SA generated $516K in revenue in Q4 2025. This represents a decrease of 88.4% from the same quarter a year earlier. Against the prior quarter it is down 78.5%.
Abivax SA's EBITDA was -$83.8M in Q4 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Abivax SA reported a net loss of $96.2M in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Abivax SA earned -$1.20 per diluted share (EPS) in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Abivax SA recorded an outflow of $27.4M in free cash flow in Q4 2025, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Abivax SA held $606.4M in cash as of Q4 2025; no long-term debt figure is on record for that period.
Not reported for Q4 2025.
Margins & Returns
Abivax SA's quarterly ROE was -18.0% in Q4 2025: one quarter's net income over shareholder equity, not annualized. This is up 79.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.0 percentage points.
Not reported for Q4 2025.
Not shown for Q4 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q4 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Abivax SA invested $52.1M in research and development in Q4 2025. This represents an increase of 30.4% from the same quarter a year earlier. Against the prior quarter it is down 19.9%.
Abivax SA invested $102K in capex in Q4 2025, funding long-term assets and infrastructure. This represents an increase of 6.1% from the same quarter a year earlier. Against the prior quarter it is up 987.6%.
Not reported for Q4 2025.
ABVX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'246-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $516K-88.4% | $2.4M+62.5% | $1.3M-78.7% | $1.1M-16.2% | $4.5M | $1.5M | $6.0M | $1.3M |
| R&D Expenses | $52.1M+30.4% | $65.0M+34.8% | $45.5M+46.9% | $42.4M+10.0% | $39.9M | $48.2M | $31.0M | $38.6M |
| Operating Income | -$84.1Mn/m | -$94.7Mn/m | -$54.7Mn/m | -$51.0Mn/m | -$44.3M | -$55.9M | -$37.8M | -$48.2M |
| EBITDA | -$83.8Mn/m | -$94.4Mn/m | -$54.4Mn/m | -$50.7Mn/m | -$44.0M | -$55.7M | -$37.4M | -$48.0M |
| Interest Expense | $43K+249.6% | $16K+22.8% | $26K+141.8% | $24K-56.8% | $12K | $13K | $11K | $55K |
| Income Tax | $6.9Mn/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 | $0 |
| Net Income | -$96.2Mn/m | -$180.0Mn/m | -$57.0Mn/m | -$56.5Mn/m | -$40.8M | -$61.6M | -$41.5M | -$46.3M |
| EPS (Basic) | -$1.20n/m | -$2.46n/m | -$0.89n/m | -$0.90n/m | -$0.65 | -$0.97 | -$0.66 | -$0.73 |
| EPS (Diluted) | -$1.20n/m | -$2.46n/m | -$0.89n/m | -$0.90n/m | -$0.65 | -$0.97 | -$0.66 | -$0.73 |
| Diluted Shares (Avg) | N/A | 73M+15.4% | 63M+0.8% | 63M+0.7% | N/A | 63M | 63M | 63M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses.
ABVX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'246-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $685.8M+222.8% | $765.2M | $140.8M | $180.2M | $212.4M-41.3% | N/A | N/A | N/A |
| Current Assets | $646.9M+266.2% | $726.7M | $101.3M | $143.2M | $176.7M-44.2% | N/A | N/A | N/A |
| Cash & Equivalents | $606.4M+306.2% | $692.0M+244.1% | $71.7M-69.9% | $111.8M-57.1% | $149.3M-46.4% | $201.1M | $238.1M | $260.7M |
| Goodwill | $21.6M+13.4% | $21.6M | $21.7M | $19.9M | $19.1M-6.4% | N/A | N/A | N/A |
| Total Liabilities | $151.6M-11.1% | $165.2M | $197.6M | $187.3M | $170.4M+17.6% | N/A | N/A | N/A |
| Current Liabilities | $74.0M-24.0% | $92.4M | $132.2M | $114.2M | $97.3M-3.0% | N/A | N/A | N/A |
| Non-Current Liabilities | $77.6M+6.1% | $72.8M | $65.4M | $73.2M | $73.1M+63.8% | N/A | N/A | N/A |
| Total Equity | $534.2M+1171.7% | $599.9M+609.4% | -$56.8M-141.9% | -$7.1M-104.2% | $42.0M-80.6% | $84.6M | $135.5M | $171.4M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Long-Term Debt, Retained Earnings.
ABVX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'246-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.3Mn/m | -$83.7Mn/m | -$39.2Mn/m | -$35.9Mn/m | -$34.7M | -$39.4M | -$54.0M | -$37.5M |
| Depreciation & Amortization | $324K+12.2% | $319K+16.9% | $295K-24.4% | $295K+29.4% | $289K | $273K | $391K | $228K |
| Capital Expenditures | $102K+6.1% | -$9K-97.3% | $22K-90.7% | $48K+266.8% | $96K | $347K | $240K | $13K |
| Free Cash Flow | -$27.4Mn/m | -$83.7Mn/m | -$39.3Mn/m | -$36.0Mn/m | -$34.8M | -$39.8M | -$54.2M | -$37.5M |
| Investing Cash Flow | -$15.0M-2698.4% | $3.8M+97.6% | $220K-98.2% | $1.2M-43.1% | $576K | $1.9M | $12.4M | $2.1M |
| Financing Cash Flow | -$46.4Mn/m | $708.2Mn/m | -$10.3M-150.4% | -$8.5M-137.0% | -$6.0M | -$7.0M | $20.5M | $22.9M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
ABVX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K | Q2'246-K | Q1'246-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -16283.6% | -3950.7% | -4254.0% | -4748.5% | -992.8% | -3790.7% | -627.7% | -3766.5% |
| Net Margin | -18627.3% | -7506.5% | -4429.5% | -5268.6% | -913.4% | -4171.2% | -688.9% | -3614.4% |
| Return on Equity | -18.0%+79.0pp | -30.0%+42.8pp | N/A | N/A | -97.0% | -72.8% | -30.7% | -27.0% |
| Return on Assets | -14.0%+5.2pp | -23.5% | -40.5% | -31.4% | -19.2% | N/A | N/A | N/A |
| Current Ratio | 8.75+6.9x | 7.86 | 0.77 | 1.25 | 1.82-1.3x | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.28-3.8x | 0.28 | N/A | N/A | 4.06+3.4x | N/A | N/A | N/A |
| Asset Turnover | 0.000.0x | 0.00 | 0.01 | 0.01 | 0.02 | N/A | N/A | N/A |
| FCF Margin | -5298.9% | -3489.5% | -3052.1% | -3352.3% | -779.6% | -2695.9% | -899.9% | -2931.4% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Abivax SA ABVX | FY2025 | $5.4M | -$394.4M | N/A | $7.6B | 52/100 |
| Rhythm Pharmaceuticals, Inc. RYTM | FY2025 | $189.8M | -$196.5M | N/A | $6.3B | 66/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $4.2B | 48/100 |
| Axsome Therapeutics, Inc AXSM | FY2025 | $638.5M | -$183.2M | -28.7% | $7.4B | 36/100 |
| Cytokinetics Inc. CYTK | FY2025 | $88.0M | -$785.0M | N/A | $8.6B | 61/100 |
Where Abivax SA Ranks
Frequently Asked Questions
What is Abivax SA's annual revenue?
Abivax SA (ABVX) reported $5.4M in total revenue for fiscal year 2025. This represents a -58.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Abivax SA's revenue growing?
Abivax SA (ABVX) revenue declined by 58.4% year-over-year, from $12.9M to $5.4M in fiscal year 2025.
Is Abivax SA profitable?
No, Abivax SA (ABVX) reported a net loss of $394.4M in fiscal year 2025.
What is Abivax SA's EBITDA?
Abivax SA (ABVX) had EBITDA of -$287.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Abivax SA's return on equity (ROE)?
Abivax SA (ABVX) has a return on equity of -73.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Abivax SA's free cash flow?
Abivax SA (ABVX) recorded an outflow of $189.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Abivax SA's operating cash flow?
Abivax SA (ABVX) recorded an outflow of $189.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Abivax SA's total assets?
Abivax SA (ABVX) had $685.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Abivax SA's capital expenditures?
Abivax SA (ABVX) invested $167K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Abivax SA spend on research and development?
Abivax SA (ABVX) invested $208.6M in research and development during fiscal year 2025.
What is Abivax SA's current ratio?
Abivax SA (ABVX) had a current ratio of 8.75 as of fiscal year 2025, which is generally considered healthy.
What is Abivax SA's liabilities-to-equity ratio?
Abivax SA (ABVX) had a liabilities-to-equity ratio of 0.28 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Abivax SA's return on assets (ROA)?
Abivax SA (ABVX) had a return on assets of -57.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Abivax SA's P/E ratio?
Abivax SA (ABVX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.6B as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Abivax SA's price-to-sales ratio?
Abivax SA (ABVX) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $5.4M revenue, FY2025). The market capitalization is $7.6B as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Abivax SA's Piotroski F-Score?
Abivax SA (ABVX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Abivax SA's earnings high quality?
Abivax SA (ABVX) reported a net loss of $394.4M while operations used $189.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Abivax SA cover its interest payments?
Abivax SA (ABVX) reported an operating loss of $288.8M against $111K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Abivax SA?
Abivax SA (ABVX) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Abivax SA it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.